{"nctId":"NCT00452439","briefTitle":"A Study of Actonel for the Prevention of Bone Loss","startDateStruct":{"date":"2004-02"},"conditions":["Leukemia","Lymphoma"],"count":72,"armGroups":[{"label":"Actonel","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Actonel (Risedronate)","Dietary Supplement: Calcium","Dietary Supplement: Vitamin D"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Dietary Supplement: Calcium","Dietary Supplement: Vitamin D"]}],"interventions":[{"name":"Actonel (Risedronate)","otherNames":["Risedronate Sodium"]},{"name":"Calcium","otherNames":[]},{"name":"Vitamin D","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age greater than or equal to 18 years\n2. Newly diagnosed ALL or LL receiving chemotherapy with augmented BFM, Hyper-CVAD or any variant of hyper-CVAD.\n3. Female patients of childbearing potential (i.e. no hysterectomy, no loss of menses for 12 consecutive months), must be willing to use contraception.\n4. Negative pregnancy test in female patients.\n5. Patients must be enrolled within 6 weeks of starting induction chemotherapy.\n\nExclusion Criteria:\n\n1. Hypocalcemia of less than 8.4 (corrected to account for the albumin level, \\[see Appendix E for formula\\])\n2. Hypersensitivity to risedronate or other bisphosphonates\n3. Inability to sit or stand upright for at least 30 minutes\n4. Bone density T-score of -2.5 S.D or less.\n5. Renal insufficiency (calculated creatinine clearance \\<30cc/min,\\[see Appendix F for formula\\])\n6. Patients with a 25-hydroxyvitamin D concentration of less than 20 ng/ml and evidence of osteomalacia (low ionized calcium and high intact PTH).\n7. Concomitant use of bisphosphonates, calcitonin, anabolic steroids, or fluoride.\n8. Corrected calcium above 10.2, due to a cause not related to leukemia/lymphoma (i.e. hyperparathyroidism, multiple myeloma).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Bone Loss Reduction: Mean Percent Changes in BMD for Each Treatment Arm at the 6 Months","description":"bone mineral density (BMD) Mean percent Change in Bone Density from Baseline to 6 months.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"0.05"},{"groupId":"OG001","value":"-3.5","spread":"0.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.6","spread":"0.06"},{"groupId":"OG001","value":"-11","spread":"0.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.2","spread":"0.06"},{"groupId":"OG001","value":"-11","spread":"0.06"}]}]}]},{"type":"PRIMARY","title":"Bone Loss Reduction: Mean Percent Changes in BMD for Each Treatment Arm at 12 Months","description":"bone mineral density (BMD) Mean percent Change in Bone Density from Baseline to 12 months","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.05"},{"groupId":"OG001","value":"-5","spread":"0.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.8","spread":"0.05"},{"groupId":"OG001","value":"-5.8","spread":"0.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.1","spread":"0.05"},{"groupId":"OG001","value":"-7","spread":"0.03"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":36},"commonTop":[]}}}